Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture

Table 1 Treatment of Acute Hereditary Angioedema - HAE - Attacks - 2010 XII 21

ANGIOEDEMA EVENT THERAPIES (AERx's)
TREAT AS EARLY AS POSSIBLE IN AN ATTACK
Plasma-derived C1 INH (pdC1INH) (intravenous)	○ Berinert^® CSL Behring - approved in many countries (including Europe and North America)
	▪ 20 units/kg intravenously (FDA licensed dose)
	○ Cetor^® Sanquin - approved in the Netherlands 1997
	▪ 1000 units intravenously
	○ Cinryze^® ViroPharma - under review for therapy
Recombinant C1INH (rhC1INH) (intravenous)	○ conestat alfa, Rhucin^® non-European and Ruconest^® in Europe; Pharming
	▪ 50 units/kg intravenously
	○ approved for use by the European Medicines Agency (EMA) for use in the European Union 2010
	○ under review in North America
Bradykinin B2 receptor antagonist (subcutaneous)	○ Icatibant - 30 mg (subcutaneous) (Firazyr^® (Jerini/Shire)
	○ approved for use by the European Medicines Agency (EMA) for use in the European Union 2008
	○ not yet approved in North America
Kallikrein receptor antagonist (subcutaneous)	○ Ecallantide, Dyax, DX-88, Kalbitor®
	○ 30 mg subcutaneously
	○ approved USA 2009 - not yet available in Canada

*Modified from: www.haecanada.com and 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema - Bowen et al. Allergy, Asthma & Clinical Immunology 2010, 6 :24 - http://www.aacijournal.com/content/6/1/24)

ISSN: 1710-1492